药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02269 药明生物

交易中 05-12 14:50:28

33.820

+0.760

+2.30%

最高34.140	最低32.940	成交量1,754万
今开33.300	昨收33.060	日振幅3.63%
总市值1,400亿	流通市值1,400亿	总股本41.41亿
成交额5.91亿	换手率0.42%	流通股本41.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"药明生物","latestPrice":33.82,"timestamp":1778568626916,"preClose":33.06,"halted":0,"volume":17539091,"delay":0,"changeRate":0.022988505747126374,"floatShares":4140999999,"shares":4140999999,"eps":1.3375147947862849,"marketStatus":"交易中","change":0.76,"latestTime":"05-12 14:50:28","open":33.3,"high":34.14,"low":32.94,"amount":590929118,"amplitude":0.036298,"askPrice":33.82,"askSize":4500,"bidPrice":33.8,"bidSize":46000,"shortable":3,"etf":0,"ttmEps":1.3375147947862849,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1778573400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1497283200000,"exchange":"SEHK","adjPreClose":33.06,"openAndCloseTimeList":[[1778549400000,1778558400000],[1778562000000,1778572800000]],"volumeRatio":0.882173,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK","impliedVol":0.4851,"impliedVolPercentile":0.2996},"requestUrl":"/m/hq/s/02269","defaultTab":"news","newsList":[{"id":"2634015154","title":"花旗：中国医疗保健行业基本面持续改善 首选药明康德(02359)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2634015154","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634015154?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:54","pubTimestamp":1778489665,"startTime":"0","endTime":"0","summary":"创新正获得回报，授权交易预付款及里程碑付款带动盈利，创新药销售加速，而CXO订单量更创下历史新高。展望未来，该行预期将有一系列短期催化剂，包括ASCO 2026年数据发布、授权交易势头持续、4月14日药品价格改革后续、CXO指引可能上调，以及市场整合加速利好医疗科技、服务及药房领导者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0979878070.USD","02359","LU0315179316.USD","LU0516423174.USD","BK1141","LU1366192091.USD","02269","LU1719994722.HKD","LU1951186391.HKD","IE0008369823.USD","SG9999004220.SGD","LU1226287792.SGD","LU1226288253.USD","LU0170899867.USD","BK1515","LU0572944931.SGD","IE00B5MMRT66.SGD","LU1997245177.USD","BK1191","LU1506573853.SGD","LU2125154935.USD","LU0203347892.USD","LU0516422366.SGD","LU2242644610.SGD","LU0314109678.HKD","LU2417539215.USD","IE00B031HY20.USD","LU1023057109.AUD","LU0098860793.USD","LU0326950275.SGD","LU0359202008.SGD","LU0307460666.USD","LU2488822045.USD","LU1008478684.HKD","LU0455707207.USD","LU1997244956.HKD","LU0980610538.SGD","BK4504","IE00BZ08YT58.USD","01276","01801","LU2360032135.SGD","01672","LU0072461881.USD","01093","LU1242518857.USD","LU2045819591.USD","LU2097828714.EUR","LU0310800965.SGD","603259"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131060708","title":"药明生物公布2026年4月股份变动月报，股本增至4,140,823,636股","url":"https://stock-news.laohu8.com/highlight/detail?id=1131060708","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131060708?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:21","pubTimestamp":1778163699,"startTime":"0","endTime":"0","summary":"2026年5月7日，药明生物发布截至2026年4月30日的股份变动月报。公告显示，公司本月内法定注册股本保持不变，仍为6,000,000,000股普通股，每股面值为USD 0.000008333333，总注册股本维持在USD 50,000。截至本月底，公司已发行普通股总数增至4,140,823,636股。公告显示，药明生物本月因行使多笔首次公开发售前购股权计划共发行新股3,030,200股，涉及募集资金总额USD 1,014,064.84。此外，药明生物表示已严格遵守包括监管部门及香港联交所《上市规则》在内的所有适用要求。公告由董事陈智胜签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633978001","title":"2025年A股高管薪酬排行榜：药明康德CEO李革近4000万元年薪高居榜首，千万元年薪高管超30人","url":"https://stock-news.laohu8.com/highlight/detail?id=2633978001","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633978001?lang=zh_cn&edition=full","pubTime":"2026-05-07 14:26","pubTimestamp":1778135178,"startTime":"0","endTime":"0","summary":"随着A股2025年报披露收官，上市公司高管年薪随之浮出水面。哪些行业上市公司高管薪酬位居前列？哪家公司高管薪酬涨幅最大？谁薪酬最高？金融业人均薪酬位居前茅从行业维度来看，申万31个一级行业中，银行业上市公司高管薪酬水平位居榜首，非银金融排名第二，美容护理位居第三，电子、医药生物行业进入前五。此外，有色金属、家用电器、电力设备、石油石化、交通运输、汽车等行业排名靠前。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605073729982450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02359","LU1688375341.USD","LU0039217434.USD","LU1997245094.SGD","LU0320764599.SGD","LU1303224171.USD","LU2039709279.SGD","LU0588546209.SGD","LU0307460666.USD","LU0327786744.USD","SG9999002463.SGD","LU1934453819.USD","LU0708995583.HKD","LU0348825331.USD","LU0819121731.USD","LU1794554557.SGD","603259","LU1242518931.SGD","LU0979878070.USD","LU0052750758.USD","LU1251922891.USD","LU0516422366.SGD","LU0572944931.SGD","SG9999002562.SGD","LU1720050803.USD","399300","LU1770034418.SGD","LU1719994722.HKD","159982","LU2488822045.USD","LU0326950275.SGD","BK1141","LU1997245177.USD","LU1880383366.USD","LU0359201612.USD","LU0456846285.SGD","LU0456827905.SGD","LU0516422952.EUR","BK1521","BK1576","LU3063872942.SGD","LU0823426308.USD","02269","LU1242518857.USD","BK1589","IE00B0JY6N72.USD","LU1969619763.USD","LU0043850808.USD","LU0140636845.USD","LU0856984785.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131242383","title":"异动解读 | 药明生物盘中大涨5.08%，年报业绩强劲及积极指引提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1131242383","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131242383?lang=zh_cn&edition=full","pubTime":"2026-05-04 11:10","pubTimestamp":1777864228,"startTime":"0","endTime":"0","summary":"药明生物今日盘中股价大幅上涨5.08%，引起了市场的广泛关注。消息面上，公司近日披露了年度报告，业绩表现十分强劲。数据显示，公司全年实现收入约217.9亿元人民币，同比增长16.7%；毛利约100.19亿元，同比增长30.9%，毛利率显著提升；归属公司拥有人净利润约56.4亿元，同比增长17.9%。此外，基于强劲的增长势头和在手订单，公司给出了积极的业绩指引，预计未来收入将实现13%-17%的同比增长，盈利可见度较高。这些利好消息显著提振了市场情绪和投资者信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137205364","title":"药明生物（02269）2025年收入与盈余强劲增长，项目储备与合规实力显著提升","url":"https://stock-news.laohu8.com/highlight/detail?id=1137205364","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137205364?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:42","pubTimestamp":1777452131,"startTime":"0","endTime":"0","summary":"药明生物于2025年度实现收入21,790,018千元人民币，较2024年度的18,675,371千元人民币增长16.7%。报告期内，公司综合财务指标整体向好：毛利由7,650,820千元人民币上升至10,018,512千元人民币，同比增幅达30.9%，毛利率从41.0%提升至46.0%。经营活动产生的现金流净额为63.41亿元人民币，较2024年度的52.17亿元人民币增长21.46%。其中，归属于公司拥有人应占净利润为5,640,299千元人民币，对比2024年度4,784,130千元人民币增长17.9%。此外，除税前溢利上升至7,256,907千元人民币，升幅为50.1%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物（02269）2025年收入与盈余强劲增长，项目储备与合规实力显著提升","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2630077463","title":"药明康德(02359)重选李革为董事会董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2630077463","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630077463?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:14","pubTimestamp":1777382066,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明康德 发布公告，董事会审议并批准重选李革博士为第四届董事会董事长，自2026年4月28 日起，至第四届董事会任期届满之日止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","LU0823426308.USD","LU1880383366.USD","LU3063872942.SGD","BK1583","BK1576","LU0051755006.USD","BK0216","LU1997245094.SGD","LU2039709279.SGD","LU1242518857.USD","SG9999002463.SGD","LU0327786744.USD","LU0348767384.USD","BK1141","LU0359201612.USD","LU0516422952.EUR","LU1997245177.USD","LU0320764599.SGD","LU0516422440.USD","02359","LU1997244956.HKD","LU0039217434.USD","02269","LU0307460666.USD","LU1808992512.USD","BK1589","LU0348825331.USD","LU0708995583.HKD","LU0417516902.SGD","LU0359202008.SGD","LU0140636845.USD","LU2242644610.SGD","LU0348735423.USD","LU0326950275.SGD","603259","LU2125910500.SGD","LU0456846285.SGD","BK1610","LU0456827905.SGD","LU2495084118.USD","LU0516423091.SGD","LU0516423174.USD","LU1688375341.USD","LU1046422090.SGD","LU1720050803.USD","LU0856984785.SGD","LU1969619763.USD","BK1521","IE00B0JY6N72.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102979103","title":"异动解读 | 行业板块普涨带动，药明生物盘中大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102979103","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102979103?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:46","pubTimestamp":1777340789,"startTime":"0","endTime":"0","summary":"药明生物今日盘中股价大幅上涨，涨幅达到5.17%，表现强劲。消息面上，药明生物所在的整个生命科学工具与服务行业今日普遍走强，形成了显著的板块效应，这被认为是推动其股价上涨的主要因素。行业内的多家公司，如药明康德、药明合联、康龙化成等，在同期均录得可观涨幅，显示出市场对该板块的关注度与投资热情有所提升。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629077324","title":"药明生物获韩国MFDS GMP认证 助力双抗生物药商业化生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2629077324","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629077324?lang=zh_cn&edition=full","pubTime":"2026-04-23 08:57","pubTimestamp":1776905879,"startTime":"0","endTime":"0","summary":"药明生物宣布，其位于无锡的三家生产厂生物药原液五厂（MFG5）、生物药制剂二厂（DP2）以及制剂包装中心（DPPC），已获韩国食品药品安全部（MFDS）GMP认证，为一款用于胆道肿瘤治疗的双特异性抗体提供涵盖原液和制剂的端到端商业化生产服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604233715266732.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233715266732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0327786744.USD","LU0588546209.SGD","LU1688375341.USD","LU0359201612.USD","BK1141","BK1576","BK1589","LU0823426308.USD","159839","LU1720050803.USD","SG9999002463.SGD","LU3063872942.SGD","LU0516422952.EUR","LU0417516902.SGD","LU0181495838.USD","LU0051755006.USD","LU0516423174.USD","LU0359202008.SGD","LU0326950275.SGD","LU0348825331.USD","LU0320764599.SGD","LU0348735423.USD","LU0516422440.USD","LU2039709279.SGD","SG9999002562.SGD","LU0708995583.HKD","LU0140636845.USD","LU0456827905.SGD","BK1521","LU0979878070.USD","LU1880383366.USD","LU0823426480.USD","IE00B0JY6N72.USD","02269","LU0516422366.SGD","LU1242518931.SGD","LU0572944931.SGD","LU0043850808.USD","LU1242518857.USD","LU0819121731.USD","LU0039217434.USD","LU1794554557.SGD","BK1610","LU0417516738.SGD","LU0856984785.SGD","LU0052750758.USD","LU0456846285.SGD","LU0307460666.USD","LU0516423091.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628799412","title":"迈威生物-B(02493)今起招股 君实生物、桂林三金及药明生物等基石认购5300万美元发售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2628799412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628799412?lang=zh_cn&edition=full","pubTime":"2026-04-20 06:34","pubTimestamp":1776638067,"startTime":"0","endTime":"0","summary":"2025年8月，迈利舒及迈卫健获巴基斯坦药品监管局上市批准。迈利舒及迈卫健是在巴基斯坦获批的首个Prolia及Xgeva生物类似药。于2024年及2025年，净亏损分别为约10.47亿元及9.72亿元，主要由于研发活动所产生的成本及开支。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","LU0516423091.SGD","LU1688375341.USD","LU0039217434.USD","BK1583","01877","LU2039709279.SGD","LU0588546209.SGD","LU0307460666.USD","002275","LU0327786744.USD","LU0516423174.USD","SG9999002463.SGD","688062","LU0819121731.USD","LU1794554557.SGD","LU0979878070.USD","LU0052750758.USD","LU0516422366.SGD","LU0572944931.SGD","SG9999002562.SGD","LU0516422440.USD","BK0188","LU0051755006.USD","LU1720050803.USD","LU0417516738.SGD","LU0326950275.SGD","LU0823426480.USD","BK0239","LU1880383366.USD","LU0348735423.USD","LU0456846285.SGD","LU0456827905.SGD","BK0060","BK1576","LU3063872942.SGD","LU0823426308.USD","02269","BK1610","LU0417516902.SGD","02493","LU1242518857.USD","BK1161","BK1589","LU0043850808.USD","BK1515","LU0140636845.USD","LU0856984785.SGD","688180","LU0181495838.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627328932","title":"2025年A股药企薪酬：药明康德李革年薪3998万，百济神州人均薪酬94万","url":"https://stock-news.laohu8.com/highlight/detail?id=2627328932","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627328932?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:00","pubTimestamp":1776250843,"startTime":"0","endTime":"0","summary":"红星资本局4月15日消息，随着年报季到来，A股已有超120家医药企业披露了2025年经营业绩，其员工薪酬也受到关注。红星资本局根据企业年报、数据统计发现，药明康德（603259.SH；2359.HK）创始人李革以3998万元的年薪暂列药企管理层第一，较第二名高出1800多万元，其连续位列A股管理层薪酬榜首。人均薪酬方面，百济神州达到94.63万元，位居第一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153706121691.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02359","LU1688375341.USD","LU0039217434.USD","BK4139","LU1997245094.SGD","ONC","BK1583","LU0320764599.SGD","LU2039709279.SGD","LU0588546209.SGD","LU0307460666.USD","06160","LU0327786744.USD","LU1934453819.USD","LU0708995583.HKD","LU0348825331.USD","LU1979443071.USD","603259","LU1046422090.SGD","LU2328871848.SGD","LU0516422366.SGD","LU0572944931.SGD","SG9999002562.SGD","LU0051755006.USD","LU1720050803.USD","LU1808992512.USD","399300","LU1770034418.SGD","LU1719994722.HKD","LU2495084118.USD","159982","LU2488822045.USD","LU2242644610.SGD","BK1576","LU3063872942.SGD","688235","BK4588","LU0456842615.SGD","02269","BK1610","BK4526","LU0417516902.SGD","LU1242518857.USD","LU1997244956.HKD","LU2125910500.SGD","BK1589","IE00B0JY6N72.USD","LU1969619763.USD","LU0043850808.USD","LU0856984785.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627245420","title":"港股概念追踪 | 创新药板块迎政策东风 国办发文健全药品价格形成机制（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2627245420","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627245420?lang=zh_cn&edition=full","pubTime":"2026-04-15 07:16","pubTimestamp":1776208598,"startTime":"0","endTime":"0","summary":"意见从4个方面提出14条举措，包括完善重点环节药品价格政策、推动相关主体发挥药品价格发现作用、引导关键领域药品价格保持合理水平、加强药品价格治理。具体举措包括优化创新药等新上市药品首发价格机制、发挥医保支付标准对药品价格形成的引导作用、健全药品集中带量采购价格形成机制、完善药品挂网价格管理。《意见》发布后，市场普遍认为新政将为医药产业特别是创新药带来发展新契机。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348825331.USD","06127","159992","BK1161","06978","LU0326950275.SGD","LU0417516902.SGD","LU0456827905.SGD","LU0819121731.USD","LU0043850808.USD","LU0823426308.USD","LU0979878070.USD","LU2045819591.USD","LU0856984785.SGD","LU2039709279.SGD","BK4585","BK1574","SG9999002463.SGD","LU0140636845.USD","LU0320764599.SGD","LU0516422366.SGD","LU0588546209.SGD","LU0708995583.HKD","IE00B0JY6N72.USD","BK1589","LU1242518931.SGD","LU0359201612.USD","LU0516423091.SGD","LU0051755006.USD","BK1610","02269","LU0359202008.SGD","LU0307460666.USD","02315","BK1583","LU0572944931.SGD","03347","LU2242644610.SGD","VXUS","LU0516422952.EUR","LU0516422440.USD","02359","LU1046422090.SGD","BK1141","LU0348735423.USD","LU0039217434.USD","LU0327786744.USD","LU1242518857.USD","LU0052750758.USD","LU0181495838.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140433994","title":"异动解读 | 药明生物盘中大涨6.18%，大手买入频现推动股价上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=1140433994","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140433994?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:05","pubTimestamp":1776153953,"startTime":"0","endTime":"0","summary":"药明生物今日盘中大涨6.18%，引起了市场的广泛关注。消息面上，该股在交易时段内多次出现大手买入。上午时段，一笔大手买入涉及资金超过900万港元。午后，另一笔大手买入涉及资金超过1000万港元。临近收盘前，再次出现一笔大手买入。这些连续的大额买单显示了市场资金的积极流入，可能反映了部分投资者对公司前景的看好，从而推动了股价在盘中的显著上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108008134","title":"药明生物3月股份变动月报表：股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1108008134","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108008134?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:42","pubTimestamp":1775724138,"startTime":"0","endTime":"0","summary":"药明生物于2026年4月9日披露2026年3月股份变动月报表。根据公告，截至3月31日，法定注册股本仍维持在6,000,000,000股，面值为每股0.000008333333美元，注册股本合计50,000美元，未发生变动。公告由董事陈智胜签署，明确表示所有股份发行及处理均符合相关上市规则及法律规定。公司股本结构在3月末保持稳定，仅因期权行使略有增加。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142172942","title":"异动解读 | CXO概念股强势，机构看好基本面拐点，药明生物盘中大涨6.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142172942","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142172942?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:33","pubTimestamp":1774924385,"startTime":"0","endTime":"0","summary":"药明生物(02269)今日盘中大涨6.38%，成为市场关注焦点。消息面上，CXO（医药研发生产外包）概念股今日表现强势，板块内多只个股同步上涨。根据机构分析，在CXO产业持续出清、股价处于相对低位的背景下，本土头部CDMO企业和受益于国内需求复苏的CRO企业正迎来底部投资机会。从财务、需求和供给数据来看，该机构认为CXO行业的基本面拐点已经出现，并有望持续复苏，这提振了市场对整个板块的信心，从而带动了药明生物等个股的股价上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623379186","title":"CXO概念股强势 凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现","url":"https://stock-news.laohu8.com/highlight/detail?id=2623379186","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623379186?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:23","pubTimestamp":1774923794,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO概念股强势，凯莱英(06821)涨13.85%，昭衍新药(06127)涨7.34%，药明生物(02269)涨5.99%，康龙化成(03759)涨4.54%，药明康德(02359)涨4.12%，泰格医药(03347)涨2.89%，金斯瑞生物科技(01548)涨1.09%。浙商医药团队分析指出，在CXO产业持续出清，股价相对低位背景下，看好本土头部CDMO企业和受益国内需求复苏CRO企业底部投资机会。从财务、需求和供给数据分析，该机构认为CXO基本面拐点已经出现，并有望持续复苏。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977810","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","01548","LU0348825331.USD","LU0588546209.SGD","LU0856984785.SGD","LU0051755006.USD","LU0359201612.USD","LU1046422090.SGD","LU0823426308.USD","LU0320764599.SGD","06821","LU0039217434.USD","LU0327786744.USD","LU0140636845.USD","LU1688375341.USD","03759","LU2045819591.USD","HK0000306701.USD","LU1880383366.USD","03347","LU0348735423.USD","LU0516422366.SGD","LU0326950275.SGD","02359","LU1794554557.SGD","LU0979878070.USD","LU1242518857.USD","LU0516423174.USD","BK1521","LU0516423091.SGD","002821","LU0572944931.SGD","LU1328615791.USD","02269","LU0043850808.USD","LU0516422440.USD","HK0000306685.HKD","LU0456846285.SGD","LU3063872942.SGD","IE00B0JY6N72.USD","LU0819121731.USD","LU0181495838.USD","LU0417516738.SGD","BK1589","LU0307460666.USD","LU0823426480.USD","LU0052750758.USD","CXO","06127","LU0456827905.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622811816","title":"大行评级丨招银国际：药明生物增长可见度有所改善，目标价上调至39港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622811816","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622811816?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:17","pubTimestamp":1774581422,"startTime":"0","endTime":"0","summary":"招银国际发表研报指，药明生物去年收入按年增长16.7%，经调整纯利按年增长17.9%，分别较该行预测高出1.2%及9.6%。根据管理层初步指引，预期今年收入增长13%至17%，如撇除外汇波动的潜在影响，料增幅将会更高。该行表示，药明生物的增长可见度有所改善，将其目标价由35.6港元上调至39港元，维持“买入”评级。该行预计公司2026至28年的收入将按年增长14.6%、16.3%及15%，而期内经调整纯利则料升18.7%、17.4%及13.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260327/32103737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143605090","title":"异动解读 | 大行下调目标价及盈利预测，药明生物盘中大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143605090","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143605090?lang=zh_cn&edition=full","pubTime":"2026-03-26 15:40","pubTimestamp":1774510857,"startTime":"0","endTime":"0","summary":"药明生物今日盘中股价出现大幅下挫，跌幅达5.01%，引起了市场关注。该行同时将公司2026年至2028年的收入预测下调了4%至8%。此外，瑞银也在其研报中下调了药明生物今明两年的每股盈利预测4%至5%，并将目标价由51.6港元微降至49.3港元。尽管瑞银维持“买入”评级，但多家大行相继下调财务预测及目标价，可能引发了投资者的担忧情绪。然而，市场似乎对下调盈利前景的报告反应更为敏感，导致了股价在交易时段的显著下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622683988","title":"中金：升药明生物(02269)目标价至48港元 维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2622683988","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622683988?lang=zh_cn&edition=full","pubTime":"2026-03-26 14:36","pubTimestamp":1774506993,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，药明生物(02269)2025年业绩高于该行预期，收入217.9亿元人民币，同比增长16.7%；净利润49.1亿元人民币，同比增长46.3%；经调整净利润56.4亿人民币，同比增长17.9%。考虑到公司经营效率提升，该行上调药明生物2026年及2027年经调整净利润6.3%及9.7%，各至62.1亿及71.9亿人民币，维持“跑赢行业”评级，上调目标价6.7%至48港元。公司业绩超该行预期，盈利能力增强主要因高利润率业务占比提升、产能利用率提高，以及营运效率提升。公司指引2026年收入将实现13-17%同比增长(考虑汇率影响)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622076038","title":"药明生物(02269)授出合共2557.5万股受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2622076038","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622076038?lang=zh_cn&edition=full","pubTime":"2026-03-25 20:58","pubTimestamp":1774443499,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明生物(02269)发布公告，于2026年3月25日，其已批准授出合共2557.5万股受限制股份奖励计划受限制股份，但须根据受限制股份奖励计划待承授人接纳，方可作实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0516422952.EUR","LU2039709279.SGD","LU0320764599.SGD","BK1576","LU0516423091.SGD","LU0823426308.USD","LU1242518931.SGD","LU1720050803.USD","LU0708995583.HKD","LU0052750758.USD","LU0979878070.USD","LU0348825331.USD","LU0051755006.USD","LU0417516902.SGD","LU1242518857.USD","LU0326950275.SGD","LU1880383366.USD","LU0307460666.USD","LU0516423174.USD","LU0181495838.USD","LU3063872942.SGD","02269","LU0327786744.USD","IE00B0JY6N72.USD","SG9999002463.SGD","LU0348735423.USD","BK1521","LU0417516738.SGD","LU0516422366.SGD","LU0516422440.USD","BK1610","LU0359202008.SGD","LU0359201612.USD","LU1794554557.SGD","BK1589","LU0572944931.SGD","LU0856984785.SGD","LU1688375341.USD","LU0588546209.SGD","LU0456827905.SGD","BK1141","LU0043850808.USD","LU0039217434.USD","LU0140636845.USD","LU0456846285.SGD","LU0819121731.USD","LU0823426480.USD","SG9999002562.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622008720","title":"药明生物 2025 年再创新高 数字原生架构驱动卓越运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2622008720","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622008720?lang=zh_cn&edition=full","pubTime":"2026-03-25 18:25","pubTimestamp":1774434300,"startTime":"0","endTime":"0","summary":"上海2026年3月25日 /美通社/ -- 全球领先的合同研究、开发和生产服务公司药明生物正式发布 2025 年年度业绩，公司业绩再创新高，运营能力亦实现显著跃升。引领实验室与工厂智能革命 今年业绩再创新高，数字原生型企业的加速转型成为关键动力。截至2025年12月底，药明生物帮助客户研发和生产的综合项目高达945个，其中包括74个临床III期项目，25个商业化生产项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4918943_ZH18943_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0327786744.USD","LU0307460666.USD","LU0823426480.USD","LU0051755006.USD","LU0516422440.USD","LU0359201612.USD","LU1242518857.USD","LU0359202008.SGD","LU0823426308.USD","LU0052750758.USD","LU0456827905.SGD","LU0348825331.USD","LU0516423174.USD","LU3063872942.SGD","BK1610","SG9999002562.SGD","LU1688375341.USD","LU0417516738.SGD","LU0979878070.USD","LU0516423091.SGD","LU1242518931.SGD","BK1589","LU0140636845.USD","LU0516422952.EUR","LU0708995583.HKD","LU0320764599.SGD","LU0572944931.SGD","BK1576","BK1141","LU1880383366.USD","LU0417516902.SGD","LU0516422366.SGD","LU0588546209.SGD","LU0819121731.USD","LU0043850808.USD","LU0181495838.USD","LU1720050803.USD","LU0348735423.USD","LU2039709279.SGD","LU0856984785.SGD","LU0326950275.SGD","LU1794554557.SGD","SG9999002463.SGD","LU0039217434.USD","BK1521","LU0456846285.SGD","02269","IE00B0JY6N72.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":-0.0434},{"period":"1month","weight":-0.0791},{"period":"3month","weight":-0.1739},{"period":"6month","weight":-0.009},{"period":"1year","weight":0.4312},{"period":"ytd","weight":0.0515}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0198},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0192},{"period":"1year","weight":0.1548},{"period":"ytd","weight":0.0303}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联（XDC）分部主要从事为抗体偶联药物（ADCs）及各种生物偶联药物提供合同研究、开发及生产组织（CRDMO）服务。该公司主要在国内和国外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052868},{"month":2,"riseRate":0.555556,"avgChangeRate":0.006907},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.001977},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000488},{"month":5,"riseRate":0.555556,"avgChangeRate":0.001543},{"month":6,"riseRate":0.625,"avgChangeRate":0.064583},{"month":7,"riseRate":0.666667,"avgChangeRate":0.081469},{"month":8,"riseRate":0.555556,"avgChangeRate":0.030253},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056337},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.033632},{"month":11,"riseRate":0.444444,"avgChangeRate":0.025584},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009161}],"exchange":"SEHK","name":"药明生物","nameEN":"WUXI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明生物,02269,药明生物股票,药明生物股票老虎,药明生物股票老虎国际,药明生物行情,药明生物股票行情,药明生物股价,药明生物股市,药明生物股票价格,药明生物股票交易,药明生物股票购买,药明生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}